Symptomatic treatment of vitreomacular adhesion (VMA).
A proteolytic enzyme that dissolves the protein matrix present in vitreomacular adhesions.
Dissolution of vitreomacular adhesion with improved vision.
Absorption: Minimal absorption
Distribution: Action is primarily local
Metabolism and Excretion: Rapidly degraded following administration
TIME/ACTION PROFILE (VMA resolution)
|Intravitreal||within 1 wk||3 wk||6 mos or more|
- None noted.
Use Cautiously in:
- Lactation:Effects are not know, use caution;
- OB: Use during pregnancy only if clearly needed;
- Pedi: Safety and effectiveness not established.
Adverse Reactions/Side Effects
May be due to procedure
EENT: blurred vision, conjunctival hemorrhage, ↓ visual acuity, eye pain, macular hole, vitreous floaters, retinal edema, anterior chamber cell, cataract, conjunctival hyperemia, dry eye, dyschromatopsia (yellow vision), ↑ intraocular pressure, intraocular inflammation/infection, intraocular hemorrhage, iritis, lens subluxation, macular edema, metamorphopsia (distorted vision), photophobia, photopsia (perceived light flashes), retinal degeneration, retinal detachment, vitreous detachment
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Intravitreal: (Adults) 0.125 mg injected as a single dose.
Solution for intravitreal injection: 0.375 mg/0.3 mL
- Monitor for elevation in intraocular pressure following injection.
- Monitor visual acuity periodically following injection; may lead to decrease in vision.
- Deficient knowledge, related to medication regimen (Patient/Family/Teaching)
- Ocriplasmin must be administered by a qualified physician.
- Intravitreal: Remove vial from freezer and allow to thaw for few min at room temperature. Solution is clear and colorless without particles; do not administer solutions that are discolored or contain particulate matter. Withdraw all solution from vial with a 19 gauge needle. Replace needle with 30 gauge needle and expel excess air and solution to 0.1 mL. Discard unused solution. Administer adequate anesthesia and a broad spectrum antibiotic as per protocol. Intravitreal injection is done via aseptic technique. Repeat administration in same eye is not recommended.
- Wait 7 days before treating other eye if necessary.
- Explain procedure for intravitreal injection to patient.
- Advise patient to notify health care professional immediately if signs and symptoms of intraocular inflammation/infection (eye redness, sensitivity to light, eye pain, change in vision) occurs.
- May cause visual changes. Advise patient to avoid driving and other activities requiring good vision until response to medication is known.
- Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
Improved vision in patients with vitreomacular adhesions.
Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Learn more.